Collegium Pharmaceutical, Inc. (COLL)

35.58 -0.36 (-1.00%) As of 11:04AM EDT. Market open.

Collegium Pharmaceutical, Inc.

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
United States
781 713 3699
https://www.collegiumpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 197

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.	Co-Founder & Independent Chairman	110k	N/A	1964
Mr. Joseph J. Ciaffoni	President, CEO & Director	1.45M	770.46k	1971
Ms. Colleen Tupper	Executive VP & CFO	782.64k	N/A	1976
Ms. Shirley R. Kuhlmann	Executive VP, General Counsel, Chief Administrative Officer & Secretary	788.45k	252.97k	1984
Mr. Scott Dreyer	Executive VP & Chief Commercial Officer	693.54k	N/A	1972
Dr. Thomas B. Smith FAAFP, M.D.	Executive VP & Chief Medical Officer	693.27k	N/A	1961
Dr. Christopher Shayne James M.D.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Bart J. Dunn	Executive Vice President of Strategy & Corporate Development	N/A	N/A	N/A
Mr. Scott Sudduth	Head of Technical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Corporate Governance

Collegium Pharmaceutical, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.